ZTS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 25.08% compared to Zoetis's net margin of 32.59%. Zoetis's return on equity of 49.71% beat Eli Lilly and's return on equity of 80.24%.

Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 22.05%. Given that Zoetis has higher upside potential than Eli Lilly and, analysts believe Zoetis is more attractive than Eli Lilly and.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Zoetis pays 31.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zoetis's net income of $581M is lower than Eli Lilly and's net income of $4.4B. Notably, Zoetis's price-to-earnings ratio is 29.48x while Eli Lilly and's PE ratio is 70.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 16.55x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 25.08% compared to Zoetis's net margin of 23.96%. Zoetis's return on equity of 49.71% beat Merck &'s return on equity of 40.25%.

Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand Merck & has an analysts' consensus of $112.29 which suggests that it could grow by 18.46%. Given that Zoetis has higher upside potential than Merck &, analysts believe Zoetis is more attractive than Merck &.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. Merck & offers a yield of 3.33% to investors and pays a quarterly dividend of $0.81 per share. Zoetis pays 31.62% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are smaller than Merck & quarterly revenues of $15.6B. Zoetis's net income of $581M is lower than Merck &'s net income of $3.7B. Notably, Zoetis's price-to-earnings ratio is 29.48x while Merck &'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 3.75x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 25.08% compared to Zoetis's net margin of 2.31%. Zoetis's return on equity of 49.71% beat Pfizer's return on equity of 8.91%.

Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 20.22%. Given that Zoetis has higher upside potential than Pfizer, analysts believe Zoetis is more attractive than Pfizer.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. Pfizer offers a yield of 6.49% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.3B, which are smaller than Pfizer quarterly revenues of $17.8B. Zoetis's net income of $581M is higher than Pfizer's net income of $410M. Notably, Zoetis's price-to-earnings ratio is 29.48x while Pfizer's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 2.33x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 25.08% compared to Zoetis's net margin of 17.38%. Zoetis's return on equity of 49.71% beat West Pharmaceutical Services's return on equity of 18.15%.

Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand West Pharmaceutical Services has an analysts' consensus of $286.12 which suggests that it could grow by 24.34%. Given that Zoetis has higher upside potential than West Pharmaceutical Services, analysts believe Zoetis is more attractive than West Pharmaceutical Services.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. West Pharmaceutical Services offers a yield of 0.36% to investors and pays a quarterly dividend of $0.21 per share. Zoetis pays 31.62% of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are larger than West Pharmaceutical Services quarterly revenues of $748.8M. Zoetis's net income of $581M is higher than West Pharmaceutical Services's net income of $130.1M. Notably, Zoetis's price-to-earnings ratio is 29.48x while West Pharmaceutical Services's PE ratio is 34.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 5.86x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.